Efficacy and safety of atorvastatin during early hospitalization in elderly patients with unstable angina

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 5-6, 2009, Pages 554-558

  Zhao, Zhuo ^b,c   Geng, Jing ^b   Ge, Zhi Ming ^b   Wang, Wei ^d   Zhang, Yun ^b   Kang, Wei Qiang ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

Author keywords

Aged inflammatory factors; Safety; Statins; Unstable angina; Vascular endothelium function

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; LIPID; TUMOR NECROSIS FACTOR ALPHA;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM;

AGED; AGED, 80 AND OVER; ANGINA, UNSTABLE; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; INFLAMMATION MEDIATORS; LENGTH OF STAY; LIPIDS; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 65349164816     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.05110.x     Document Type: Article

References (25)

1. Correia LC, Spósito AC, Lima JC et al. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am. J. Cardiol. 2003 92 : 298 301. (Pubitemid 36897715)
2. Kinlay S, Schwartz GG, Olsson AG et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003 108 : 1560 6. (Pubitemid 37187781)
3. Davies MJ. Stability and instability; two faces of coronary atherosclerosis. Circulation 1996 94 : 2013 20.
4. Libby P. Current concepts of pathogenesis of acute soronary syndromes. Circulation 2001 104 : 365 72. (Pubitemid 32666962)
5. Fonarow GC, Wright SR, Spencer FA et al. Effect of statin use within the first 24 h of admission for acute myocardial infarction on early morbidity and mortality. Am. J. Cardiol. 2005 96 : 611 16. (Pubitemid 41207298)
6. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am. J. Cardiol. 2007 99 : 1538 43. (Pubitemid 46770637)
7. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID Trial. JAMA 2006 295 : 1556 65.
8. Braunwald E. Unstable angina. A classification. Circulation 1989 80 : 410 14. (Pubitemid 19195751)
9. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 340 : 1111 15.
10. Libby P. Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr. 2006 83 (Suppl 456 60.
11. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 2002 347 : 1557 65. (Pubitemid 35315836)
12. Ridker PM, Hennekens CH, Buring JE, Rifal N. C-Reactive protein and other makers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000 342 : 836 43. (Pubitemid 30165206)
13. Anderson TJ, Meredith IT, Yeung AC et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 1995 332 : 488 93.
14. Järvisalo MJ, Toikka JO, Vasankari T et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999 147 : 237 42. (Pubitemid 29512254)
15. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001 285 : 1711 18. (Pubitemid 32259905)
16. Arntz HR, Agrawal R, Wunderlich W et al. Beneficial effects of pravastatin (+/-cholestiramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am. J. Cardiol. 2000 86 : 1293 8.
17. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004 291 : 1071 80. (Pubitemid 38541684)
18. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004 350 : 1495 504. (Pubitemid 38477774)
19. Ridker PM, Morrow DA, Rose LM, Rifal N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol < 70 mg/dL and C-reactive protein < 2 mg/L: An analysis of the PROVE-IT TIMI-22 trial. J. Am. Coll. Cardiol. 2005 45 : 1644 8. (Pubitemid 40704500)
20. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann. Intern. Med. 2007 147 : 1 9.
21. Avezum A, Makdisse M, Spencer F et al. Impact of age on management and outcome of acute coronary syndrome: Observations from the global registry of acute coronary events (GRACE). Am. Heart J. 2005 149 : 67 73. (Pubitemid 40126492)
22. Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am. J. Cardiol. 2004 94 : 882 8. (Pubitemid 39349552)
23. Shepherd J, Vidt DG, Miller E. Safety of rosuvastatin: Update on 16 876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007 107 : 433 43. (Pubitemid 46788271)
24. Maroo BP, Lavie CJ, Milani RV. Efficacy and safety of intensive statin therapy in the elderly. Am. J. Geriatr. Cardiol. 2008 17 : 92 100.
25. Patel JV, Gupta S, Lie F, Hughes EA. Efficacy and safety of atorvastatin in south Asian patients with dyslipidemia: An open label noncomparative pilot study. Vasc. Health Risk Manag. 2005 1 : 351 6.